IGF-1 DES
Also known as: DES(1-3)IGF-1, IGF-1 DES(1,3)
Status
No approved product. No FDA-approved labeling. Not an approved medicine in the United States, and no approval elsewhere is listed in this site's sources.
What it is
A shortened IGF-1 variant with far lower binding-protein affinity and a very short life in the body.
What published research measured
Missing the first three amino acids of native IGF-1, which is the part that binds IGF binding proteins. With that affinity largely gone it is cleared in around twenty minutes rather than circulating bound for hours, and the practical consequence is that essentially all published work is cell-culture or animal. No published human trial was identified that establishes an effect on body composition, and its potency at the insulin receptor is the reason hypoglycemia is the recurring theme in reports.
Source
Bredehöft M et al. 2008 — Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liqui… · Pan W et al. 2000 — Interactions of IGF-1 with the blood-brain barrier in vivo and in situ
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.